US Dollar vs Yen

登録してリアルタイムのチャート、分析ツール、価格を入手してください。

ホーム
投資
株式
イギリス
LSE
Abionyx Pharma (0RAG) 銘柄情報

Abionyx Pharma (0RAG)

2.03

0.00

(0.00%)

終了 6月11日 12:30AM

Abionyx Pharma (0RAG) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

2.03

( - )

買値

2.03

売値

2.03

出来高

0.00

0.00 日の範囲 0.00

2.03 52 週間の範囲 2.03

時価総額

前日終値

2.03

始値

-

時刻

最終取引時間

財務取引量

-

VWAP

-

平均取引量 (3 か月)

151,055 €

発行済株式数

35,293,050

配当利回り

PER

-17.13

1 株当たり利益 (EPS)

-0.16

歳入

4.06M

純利益

-5.55M

ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (... ABIONYX Pharma SA, a biotech company, discovers and develops therapies for the treatment of renal, metabolic, and ophthalmic diseases in France and the United States. It operates through Research and Development Activities for the Development of Innovative Drugs; and Contract Research Organization (CRO) Activities segments. The company develops CER-001, a recombinant HDL mimetic biopharmaceutical in a Phase III trial for the treatment of lecithin cholesterol acyltransferase (LCAT) deficiency, as well as in a Phase II trial for the treatment of sepsis. It is also developing ABNX-100, a strategic extension into ophthalmology of CER-001 that is in preclinical trial for the treatment of uveitis. The company was formerly known as Cerenis Therapeutics Holding SA and changed its name to ABIONYX Pharma SA in August 2019. ABIONYX Pharma SA was incorporated in 2005 and is headquartered in Balma, France. 詳細を表示

セクター

-

業界

-

ウェブサイト

abionyx.com

本社

Balma, France

設立

2026

Abionyx Pharma is listed in the sector of the ロンドン証券取引所 with ticker 0RAG. The last closing price for Abionyx Pharma was 2.03 €. Over the last year, Abionyx Pharma shares have traded in a share price range of 2.03 € to 2.03 €.

Abionyx Pharma currently has 35,293,050 shares in issue. The market capitalisation of Abionyx Pharma is 71.64 € million. Abionyx Pharma has a price to earnings ratio (PE ratio) of -17.13.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	2.03	2.03	2.03	355	2.03	DE
52	0	0	2.03	2.03	2.03	4832	2.03	DE
156	0	0	2.03	2.03	2.03	1745	2.03	DE
260	0	0	2.03	2.03	2.03	1490	2.03	DE

0RAG - Frequently Asked Questions (FAQ)

What is the current Abionyx Pharma share price?

The current share price of Abionyx Pharma is 2.03 €

How many Abionyx Pharma shares are in issue?

Abionyx Pharma has 35,293,050 shares in issue

What is the market cap of Abionyx Pharma?

The market capitalisation of Abionyx Pharma is EUR 71.64M

What is the 1 year trading range for Abionyx Pharma share price?

Abionyx Pharma has traded in the range of 2.03 € to 2.03 € during the past year

What is the PE ratio of Abionyx Pharma?

The price to earnings ratio of Abionyx Pharma is -17.13

What is the cash to sales ratio of Abionyx Pharma?

The cash to sales ratio of Abionyx Pharma is 23.8

What is the registered address of Abionyx Pharma?

The registered address for Abionyx Pharma is Building D2, Balma, Midi-Pyrénées, 31130

What is the Abionyx Pharma website address?

The website address for Abionyx Pharma is abionyx.com

ScottishTexan

ScottishTexan 4分前

Right. Nonsense.

benyam

hit today 9500 right now shares and ask up

ollik78

ollik78 5分前

CIIT … POP in AH 🚬🤷‍♂️ lets find out

SSKILLZ1

SSKILLZ1 6分前

SSKMP Trades

Buy 150 Shares of ASO
Buy 10 Shares of INTU

Note that this is a fictional portfolio and is not a recommendation to buy or sell securities

Cosa

Added today, this is the all time low. It doesn't look like it's going to get better soon either 😂.

vlispxpert

vlispxpert 6分前

SMMT-6.5M x $12..55 (low of day) $81.5M...so $75M offering nothing imo...I think they chose $75M based on latest daily average..jmho Now watch for offering closed & some kind of big news...guess we see ;)

work-n-hard

work-n-hard 7分前

Ahhhh, was wondering if we would get a different outcome in the last 30 mins.
Bidders seeing that the selling won't go on and move to the Smacky Tactic???

litkillah

litkillah 7分前

Would love to agree but if the Circuit Judge gets reversed then it means first decision was right (to dismiss)
Im from Europe but in our law system you cannot use evidence gathered out of a procedure so probably all the info gathered is useless
I would love to be mistaken so more than

Craig305

Craig305 7分前

That video also says the Assissi Loop costs $450. That is false. You can get for $330. What bias to throw out untruths. 😄

Sammy boy

Sammy boy 7分前

Are we still blaming it on OTC or No Rush ?

Glycobio

Glycobio 7分前

sunspotter that link/article you bring up is from two years ago before they had the complete results.

The publication below, in contrast, is current with recent clinical trial results.

That’s weak of you to bash with old info. Take some time to read the latest.

glenn1919

glenn1919 7分前

SNBR................................https://stockcharts.com/sc3/ui/?s=SNBR&p=w&b=5&g=0&id=p86431144783

Cornerstone_Marketing

Cornerstone_Marketing 8分前

https://x.com/cs_marketinginc/status/2064778907438535124?s=46

Cornerstone_Marketing

Cornerstone_Marketing 9分前

https://x.com/cs_marketinginc/status/2064761291349102762?s=46

otcsource

otcsource 9分前

Buy: 86,956,019 Neutral: 25,000 Sell: 40,100
Time Price Size Type B/S Bid Price Ask Price Total Volume Num Exch.
15:15:08 0.0001 16,105,000 Buy 0.0001 0.0001 87,021,119 78 nasd
15:15:08 0.0001 3,870,000 Buy 0.0001 0.0001 70,916,119 77 nasd
15:15

TenKay

TenKay 10分前

And yet… the stock is 0.0001X0.0002 on anemic volume.

Seriously…it’s done.

Oleblue

Oleblue 10分前

Looks like the GDX has now broken the 50 and 200 DMA and the next support is at 70.

With all the paper trading in gold and silver, who knows where it will land.

Daily GDX
https://schrts.co/MDMAVWJg

Honey has support at $.48 and the 50 DMA should ra

BlazingStocks

BlazingStocks 10分前

Emerging biotech companies often spend years proving their technology.
$MAJI appears focused on proving the technology AND bringing products to market.
That distinction matters.
Revenue generation is where development stories become growth stories.
#MAJI #BiotechGrowth #H

Nox32

Are you referencing this for the pilot?

March 5, 2026 — Atlas "major milestone"

KBLB said Project Atlas passed its "most critical milestone." The project is aimed at creating new industrial and defense biomaterials, not just more spider silk. They stated Atlas had alre

Porch Honkey

Porch Honkey 11分前

$ECOX,
If they follow through on their promises and these catalysts are met, I can easily see this reaching 4 cents.

seve333

seve333 11分前

100% like Jron said this would have been the icing on the cake but the new formulation was always going to be the game changer that will move the stock to 200 overnight. Its a matter of when not if now. Jron is loading up the boat who else is?

US Market News

US Market News 12分前

More Racing, More Performance, More Smoke, More Horsepower: MotorTrend Presents Roadkill Nights Powered by Dodge Expands to Two Tracks, Direct Connection Grudge Match Is Back!June 10, 2026 3:15 PM
PR Newswire (US) class="legendSpanClass"AUBURN HILLS, M

SmoothTrader61

SmoothTrader61 12分前

I am bellied up to the bar for 100k but no one serving me, I will wait and if I don’t get served soon then I will serve myself I guess

4gh1rx

4gh1rx 12分前

Axxa assets, revenues, profit

$AXXA

Axxa truly has $152MM assets, $30.21MM gross profts, $8.1 net profit --- and all for just $0.0003. Right?

https://media.tenor.com/fcFXW9hdYBQAAAAM/shano-don-shano.gif
You can trust 'em on that.

Norwest Energy Nl

BlackRock Institutional ...

Global X Ai UCITS ETF

0.250% until 6/29/2029 0...

Bmo Fixed Income Etf Por...

Amplify AI Powered Equit...

Nexans Paris ACT (PK)

Tasman Resources

Vanguard ESG EUR Corpora...

VanEck India Growth Lead...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。